NPI: 1467833673 · ELIZABETHTON, TN 37643 · Internal Medicine Physician · NPI assigned 06/12/2015
Authorized official KILGORE, CARL controls 20+ related entities in our dataset. Read more
| Authorized Official | KILGORE, CARL (PRESIDENT) |
| NPI Enumeration Date | 06/12/2015 |
Other providers sharing the same authorized official: KILGORE, CARL
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 4,673 | $156K |
| 2019 | 3,128 | $96K |
| 2020 | 3,155 | $85K |
| 2021 | 12,780 | $591K |
| 2022 | 23,791 | $661K |
| 2023 | 22,126 | $514K |
| 2024 | 23,612 | $705K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24,573 | 20,979 | $1.03M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5,152 | 4,030 | $534K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7,196 | 5,981 | $391K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 9,563 | 7,856 | $270K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4,944 | 4,066 | $211K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2,493 | 1,834 | $180K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3,709 | 3,045 | $70K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 753 | 669 | $41K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,983 | 2,662 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,783 | 1,320 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 485 | 437 | $18K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 290 | 248 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 101 | 77 | $2K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 14 | 12 | $1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 73 | 65 | $1K |
| 99201 | 31 | 30 | $974.65 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 25 | 19 | $769.65 |
| 87634 | 37 | 26 | $598.98 | |
| 3074F | 13,349 | 12,083 | $200.00 | |
| 3079F | 2,010 | 1,880 | $175.00 | |
| 81003 | 74 | 63 | $137.82 | |
| 3078F | 11,009 | 10,023 | $100.00 | |
| 3075F | 1,003 | 914 | $75.00 | |
| 81002 | 57 | 52 | $35.84 | |
| 3077F | 368 | 319 | $25.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 21 | 12 | $12.92 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 14 | 12 | $6.37 |
| 3080F | 74 | 63 | $0.00 | |
| 4010F | 81 | 65 | $0.00 |